Chugai Pharmaceutical Co., Ltd.
4519
Rang in Aktien
#346
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Aktienkurs
$42.53
Marktkapitalisierung
$69.98B
Veränderung (1 Tag)
1.37%
Veränderung (1 Jahr)
-14.40%
Land
JP
Handel Chugai Pharmaceutical Co., Ltd. (4519)
Kategorie
Healthcare
Kursverlauf für Chugai Pharmaceutical Co., Ltd. (4519)
Höchster Schlusskurs: $38.86 am 2026-10-01
Niedrigster Schlusskurs: $51.75 am 2000-11-01
Niedrigster Schlusskurs: $51.75 am 2000-11-01
Kursverlauf der Aktie von Chugai Pharmaceutical Co., Ltd. von 2000 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -7.35% |
| 2025 | 24.85% |
| 2024 | 17.22% |
| 2023 | 54.46% |
| 2022 | -26.90% |
| 2021 | -29.65% |
| 2020 | 549.58% |
| 2019 | -29.61% |
| 2018 | 118.94% |
| 2017 | 21.69% |
| 2016 | -66.07% |
| 2015 | 245.37% |
| 2014 | 26.29% |
| 2013 | -97.98% |
| 2012 | 161.03% |
| 2011 | -12.65% |
| 2010 | -8.22% |
| 2009 | 13.93% |
| 2008 | 6.97% |
| 2007 | -20.27% |
| 2006 | -7.51% |
| 2005 | 47.49% |
| 2004 | 2.63% |
| 2003 | 84.70% |
| 2002 | -39.16% |
| 2001 | -23.39% |
| 2000 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $1.27K | 56.64% |
US
|
|
| $257.61 | 33.52% |
US
|
|
| $284.48 | 24.40% |
US
|
|
| $149.84 | 71.03% |
US
|
|
| $482.98 | 31.03% |
CH
|
